New insights into the role of endogenous opioids in the pathogenesis of gastrointestinal and liver disease

Gut

Volumn 58, Issue 7, 2009, Pages 893-895

  Mani, Ali R ^a,b   Moore, Kevin P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; ENDORPHIN; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR;

BILIARY TRACT DISEASE; ENTERITIS; GASTROINTESTINAL DISEASE; HEPATITIS C VIRUS; HUMAN; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; STELLATE CELL; WILD TYPE;

ANIMALS; BILIARY TRACT DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; NEUROTRANSMITTER AGENTS; OPIOID PEPTIDES; PANCREATIC NEOPLASMS;

EID: 67649669095     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2007.141648     Document Type: Short Survey

References (29)

1. Hughes J, Smith TW, Kosterlitz HW, et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975;258:577-580
2. Madden JJ, Whaley WL, Ketelsen D. Opiate binding sites in the cellular immune system: expression and regulation. J Neuroimmunol 1998;83:57-62. (Pubitemid 28280951)
3. Marzioni M, Alpini G, Saccomanno S, et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology 2006;130:1831-1847 (Pubitemid 43668860)
4. Ebrahimkhani MR, Kiani S, Oakley F, et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006;55:1606-1616 (Pubitemid 44629212)
5. De Minicis S, Candelaresi C, Marzioni M, et al. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. Gut 2008;57:352-364 (Pubitemid 351288102)
6. Philippe D, Dubuquoy L, Groux H, et al. Antiinflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 2003;111:1329-1338 (Pubitemid 36554703)
7. Bergasa NV, Sabol SL, Young WS 3rd, et al. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995;268(2 Pt 1):G346-54
8. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-549
9. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002;38:351-376 (Pubitemid 34219111)
10. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:918-932 (Pubitemid 47203871)
11. Philippe D, Chakass D, Thuru X, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut 2006;55:815-823 (Pubitemid 43764552)
12. Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol 2003;521:148-160 (Pubitemid 36535172)
13. Gadano A, Moreau R, Pessione F, et al. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 2000;32:38-42. (Pubitemid 30039445)
14. Mani AR, Rasool R, Montagnese S, et al. Endogenous opioids and liver disease. Scand J Gastroenterol 2006;41:1-11. (Pubitemid 43030885)
15. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007;132:415-431 (Pubitemid 46108729)
16. Ebrahimkhani MR, Elsharkawy AM, Mann DA. Wound healing and local neuroendocrine regulation in the injured liver. Expert Rev Mol Med 2008 29;10:e11 (Pubitemid 351622226)
17. Marzioni M, Svegliati Baroni G, Alpini G, et al. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 2007;46:583-586 (Pubitemid 46431168)
18. Roberts SM, Skoulis NP, James RC. A centrally-mediated effect of morphine to diminish hepatocellular glutathione. Biochem Pharmacol 1987;36:3001-3005 (Pubitemid 17142307)
19. Wittert G, Hope P, Pyle D. Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 1996;218:877-881 (Pubitemid 26050757)
20. Jaume M, Jacquet S, Cavailles P, et al. Opioid receptor blockade reduces Fas-induced hepatitis in mice. Hepatology 2004;40:1136-1143 (Pubitemid 39425569)
21. Moore K, Dusheiko G. Opiate abuse and viral replication in hepatitis C. Am J Pathol 2005;167:1189-1191 (Pubitemid 41541406)
22. Li Y, Zhang T, Douglas SD, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003;163:1167-1175 (Pubitemid 37040152)
23. Zagon IS, Smith JP, Conter R, et al. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma. Int J Mol Med 2000;5:77-84.
24. Zagon IS, Hytrek SD, Smith JP, et al. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett 1997;112:167-175 (Pubitemid 27104987)
25. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 1999;14:577-584
26. Zagon IS, Jaglowski JR, Verderame MF, et al. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2005;56:510-520 (Pubitemid 41549153)
27. Smith JP, Conter RL, Bingaman SI, et al. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs 2004;15:203-209 (Pubitemid 38429411)
28. McCarthy L, Wetzel M, Sliker JK, et al. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001;62:111-123 (Pubitemid 32195501)
29. Pinzani M. Pancreatic stellate cells: new kids become mature. Gut 2006;55:12-14 (Pubitemid 41820628)